The overarching goal of the HCCC Experimental Therapeutics (ET) program is to develop and test novel cancer therapeutics. To accomplish this, ET has three central research themes: 1) Therapeutic Targets and Lead Discovery, 2) Novel Drug Delivery Approaches and 3) Clinical Therapeutics. ET has 30 full members and 17 associate members. Members have appointments across 3 colleges (Medicine, Pharmacy and Liberal Arts and Sciences) and 11 departments. Many ET members contribute to more than one theme. Total peer- reviewed annual research funding to ET is $4.33 million ($2.44 from the NCI) with $10.44 million in funding for non-peer reviewed research projects. ET members are highly productive and collaborative. ET members have authored or co-authored 305 cancer-related publications since April 1, 2011 with 49% (n=148) addressing therapeutic targets and lead discovery, 14% (n=43) addressing novel drug delivery approaches and 36% (n=108) addressing clinical therapeutics. 19% (n=59) were intra-programmatic, 37% (n=113) inter- programmatic, and 30% (n=93) inter-institutional. 26 manuscripts were published in high impact journals (impact factor >10). In the Therapeutic Targets and Lead Discovery theme, groups of investigators collaborate based on experimental therapeutics geared towards specific pathways, as well as cancer types. In the Novel Drug Delivery Approaches theme, ET investigators are evaluating nanoparticles, aptamers and novel approaches to cancer immunotherapy for treating prostate cancer, lymphoma, melanoma and breast cancer. Investigators in the Clinical Therapeutics theme are exploring mechanisms of action of clinical therapeutics and participating in or leading 145 active clinical trials across a spectrum of cancer types as coordinated through the disease specific Multidisciplinary Oncology Groups (MOGs). As a program, an increasing focus of ET is to facilitate movement of promising molecularly-targeted therapeutic approaches through the developmental therapeutics pipeline.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA086862-17
Application #
9252417
Study Section
Subcommittee A - Cancer Centers (NCI-A)
Project Start
Project End
Budget Start
2017-04-01
Budget End
2018-03-31
Support Year
17
Fiscal Year
2017
Total Cost
$21,116
Indirect Cost
$7,270
Name
University of Iowa
Department
Type
Domestic Higher Education
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52246
Brooks, Jennifer D; Comen, Elizabeth A; Reiner, Anne S et al. (2018) CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study. Breast Cancer Res 20:149
Chioreso, Catherine; Del Vecchio, Natalie; Schweizer, Marin L et al. (2018) Association Between Hospital and Surgeon Volume and Rectal Cancer Surgery Outcomes in Patients With Rectal Cancer Treated Since 2000: Systematic Literature Review and Meta-analysis. Dis Colon Rectum 61:1320-1332
Musselman, Catherine A; Kutateladze, Tatiana G (2018) A histone reader becomes the readout. J Biol Chem 293:7486-7487
Merritt, Nicole M; Fullenkamp, Colleen A; Hall, Sarah L et al. (2018) A comprehensive evaluation of Hippo pathway silencing in sarcomas. Oncotarget 9:31620-31636
Haskins, Cole B; McDowell, Bradley D; Carnahan, Ryan M et al. (2018) Impact of preexisting mental illness on breast cancer endocrine therapy adherence. Breast Cancer Res Treat :
Daneshmand, Siamak; Patel, Sanjay; Lotan, Yair et al. (2018) Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study. J Urol 199:1158-1165
Kim, Yusung; Cabel, Katherine; Sun, Wenqing (2018) Does the apex optimization line matter for single-channel vaginal cylinder brachytherapy planning? J Appl Clin Med Phys 19:307-312
Hagan, Teresa L; Gilbertson-White, Stephanie; Cohen, Susan M et al. (2018) Symptom Burden and Self-Advocacy: Exploring the Relationship Among Female Cancer Survivors?. Clin J Oncol Nurs 22:E23-E30
Chesney, Jason; Puzanov, Igor; Collichio, Frances et al. (2018) Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. J Clin Oncol 36:1658-1667
Kleinstern, Geffen; Maurer, Matthew J; Liebow, Mark et al. (2018) History of autoimmune conditions and lymphoma prognosis. Blood Cancer J 8:73

Showing the most recent 10 out of 1080 publications